2 weeks Ago By Defense World Staff
Gilead Sciences ( NASDAQ:GILD – Get Free Report ) and Taysha Gene Therapies ( NASDAQ:TSHA – Get Free Report ) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Analyst Recommendations This is a summary of recent recommendations and price targets for Gilead Sciences and Taysha Gene Therapies, as provided by MarketBeat.com.
Gilead Sciences currently has a consensus price target of $91.50, suggesting a potential downside of 5.70%.
Taysha Gene Therapies has a consensus price target of $6.38, suggesting a potential upside of 291.10%.
Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Gilead Sciences. Profitability Volatility & Risk Gilead Sciences has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
Comparatively, Taysha Gene Therapies has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Insider and Institutional Ownership 83.
7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors.
0.2% of Gilead Sciences shares are owned by insiders. Comparatively, 2.
7% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Earnings and Valuation This table compares Gilead Sciences and Taysha Gene Therapies”s revenue, earnings per share and valuation.
Gilead Sciences has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. Summary Gilead Sciences beats Taysha Gene Therapies on 10 of the 15 factors compared between the two stocks.
About Gilead Sciences ( Get Free Report ) Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.
; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.
; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.
; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.
V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
About Taysha Gene Therapies ( Get Free Report ) Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc.
was incorporated in 2019 and is headquartered in Dallas, Texas. Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
